8-K: Ainos Extends Patent Use Agreement with TCNT for VOC and POCT Technologies

Ainos, Inc. has extended its agreement with Taiwan Carbon Nano Technology Corporation (TCNT) for non-exclusive use of patents related to volatile organic compounds (VOC) and point-of-care testing (POCT) technologies for an additional three months.

Summary

• Ainos, Inc. has entered into a second addendum to its product development agreement with Taiwan Carbon Nano Technology Corporation (TCNT).
• This addendum extends the non-exclusive use of certain patents related to volatile organic compounds (VOC) and point-of-care testing (POCT) technologies.
• The extension covers an additional three months, from July 2024 to September 2024.
• Ainos will pay a monthly fee of US$95,000 (plus 5% sales tax) for the patent use during this period.
• The original product development agreement was signed on August 1, 2021, and a first addendum was signed on January 9, 2024.
• TCNT holds a majority share of Ainos Inc., a Cayman Islands corporation, which holds approximately 39% of the voting power of Ainos, Inc. as of July 8, 2024.
• The co-development fee is NT$5 million (approximately USD$161,000) over a five-year period from 2024.

Sentiment

Score: 6

Explanation: The document indicates a continuation of existing agreements, which is generally neutral. The ongoing costs are a slight negative, but the continued access to technology is a positive.

Positives

• The extension of the patent use agreement allows Ainos to continue its development efforts in VOC and POCT technologies.
• The agreement provides access to TCNT's facilities, equipment, and mass production process technology.

Negatives

• The company is incurring a monthly expense of US$95,000 (plus 5% sales tax) for the patent use.
• The agreement is non-exclusive, meaning TCNT can license the same patents to other parties.

Risks

• The ongoing cost of US$95,000 per month for patent use could impact profitability.
• The non-exclusive nature of the patent license could lead to increased competition.
• The company is reliant on TCNT for facilities, equipment, and mass production process technology.

Future Outlook

The parties may negotiate payment terms and subsequent licensing methods for the patents after the three-month extension.

Management Comments

• The foregoing description of the Second Addendum Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Addendum Agreement.

Industry Context

This agreement is relevant to the medical device and pharmaceutical industries, particularly in the areas of diagnostics and point-of-care testing. The use of VOC and POCT technologies is a growing trend in healthcare.

Comparison to Industry Standards

• Licensing agreements for technology and patents are common in the pharmaceutical and medical device industries.
• The monthly fee of US$95,000 for patent use is within the range of similar agreements, but the specific terms and value depend on the technology and market potential.
• Companies like Abbott and Roche also invest heavily in point-of-care testing technologies, but their agreements and development strategies are not directly comparable without more specific details.

Related Party Transactions

• TCNT, a majority shareholder of Ainos Inc., is a related party in this transaction.

Stakeholder Impact

• Shareholders may view the extension of the agreement as a positive step in product development.
• Employees involved in R&D will continue to work on the co-development projects.
• Customers may benefit from the development of new products using the licensed technologies.

Next Steps

• Ainos will continue to utilize the licensed patents for product development.
• The parties may negotiate payment terms and subsequent licensing methods after the three-month extension.

Key Dates

Keywords

Product Development, Patent Licensing, Volatile Organic Compounds, Point-of-Care Testing, Technology, Pharmaceuticals, Medical Devices, Manufacturing